Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMLX NASDAQ:COYA NASDAQ:RAPP NASDAQ:RVNC On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMLXAmylyx Pharmaceuticals$8.34+0.7%$5.88$1.76▼$8.59$743.44M-0.491.15 million shs1.13 million shsCOYACoya Therapeutics$5.81-2.5%$5.80$4.65▼$10.24$97.17M0.2673,703 shs99,683 shsRAPPRapport Therapeutics$14.68-1.1%$11.68$6.43▼$29.74$535.79MN/A166,071 shs137,409 shsRVNCRevance Therapeutics$3.65$3.65$2.76▼$6.65$381.02M0.93.76 million shsN/A5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMLXAmylyx Pharmaceuticals+0.72%+8.59%+63.53%+109.55%+293.40%COYACoya Therapeutics-2.52%-5.22%+5.44%+10.46%-18.97%RAPPRapport Therapeutics-1.08%+0.55%+33.09%+44.63%-43.86%RVNCRevance Therapeutics0.00%0.00%0.00%0.00%-7.83%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMLXAmylyx Pharmaceuticals3.2758 of 5 stars4.51.00.00.02.52.50.6COYACoya Therapeutics1.8718 of 5 stars3.53.00.00.00.00.80.0RAPPRapport Therapeutics1.3075 of 5 stars3.50.00.00.01.00.80.6RVNCRevance Therapeutics2.7297 of 5 stars3.10.00.04.70.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMLXAmylyx Pharmaceuticals 3.00Buy$11.7540.89% UpsideCOYACoya Therapeutics 3.00Buy$16.50183.99% UpsideRAPPRapport Therapeutics 3.00Buy$28.0090.74% UpsideRVNCRevance Therapeutics 2.13Hold$8.45131.51% UpsideCurrent Analyst Ratings BreakdownLatest COYA, RVNC, RAPP, and AMLX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/10/2025AMLXAmylyx PharmaceuticalsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy$10.007/9/2025COYACoya TherapeuticsLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$16.007/8/2025RAPPRapport TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$28.007/1/2025COYACoya TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.006/24/2025AMLXAmylyx PharmaceuticalsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageHold6/24/2025AMLXAmylyx PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold6/24/2025AMLXAmylyx PharmaceuticalsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$17.006/17/2025AMLXAmylyx PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.006/9/2025COYACoya TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.005/30/2025AMLXAmylyx PharmaceuticalsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy5/14/2025AMLXAmylyx PharmaceuticalsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$7.00 ➝ $8.00(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMLXAmylyx Pharmaceuticals$87.37M8.51N/AN/A$2.40 per share3.48COYACoya Therapeutics$3.55M27.38N/AN/A$2.37 per share2.45RAPPRapport TherapeuticsN/AN/AN/AN/A$8.35 per shareN/ARVNCRevance Therapeutics$234.04M1.63N/AN/A($1.73) per share-2.11Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMLXAmylyx Pharmaceuticals-$301.74M-$3.11N/AN/AN/AN/A-77.21%-63.84%8/6/2025 (Estimated)COYACoya Therapeutics-$14.88M-$1.07N/AN/AN/AN/A-48.88%-43.32%8/11/2025 (Estimated)RAPPRapport Therapeutics-$78.31M-$3.45N/AN/AN/AN/A-25.48%-24.63%8/14/2025 (Estimated)RVNCRevance Therapeutics-$323.99M-$1.93N/AN/AN/A-74.67%N/A-37.22%8/6/2025 (Estimated)Latest COYA, RVNC, RAPP, and AMLX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025AMLXAmylyx Pharmaceuticals-$0.43N/AN/AN/AN/AN/A8/14/2025Q2 2025RAPPRapport Therapeutics-$0.87N/AN/AN/AN/AN/A8/11/2025Q2 2025COYACoya Therapeutics-$0.22N/AN/AN/AN/AN/A5/13/2025Q1 2025COYACoya Therapeutics-$0.44-$0.44N/A-$0.44$2.63 million$257.88 million5/8/2025Q1 2025AMLXAmylyx Pharmaceuticals-$0.45-$0.42+$0.03-$0.42N/AN/A5/8/2025Q1 2025RAPPRapport Therapeutics-$0.77-$0.68+$0.09-$0.68N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMLXAmylyx PharmaceuticalsN/AN/AN/AN/AN/ACOYACoya TherapeuticsN/AN/AN/AN/AN/ARAPPRapport TherapeuticsN/AN/AN/AN/AN/ARVNCRevance TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMLXAmylyx PharmaceuticalsN/A12.0512.05COYACoya TherapeuticsN/A8.848.84RAPPRapport TherapeuticsN/A31.0131.01RVNCRevance TherapeuticsN/A4.123.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMLXAmylyx Pharmaceuticals95.84%COYACoya Therapeutics39.75%RAPPRapport TherapeuticsN/ARVNCRevance Therapeutics97.70%Insider OwnershipCompanyInsider OwnershipAMLXAmylyx Pharmaceuticals11.70%COYACoya Therapeutics12.00%RAPPRapport TherapeuticsN/ARVNCRevance Therapeutics5.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMLXAmylyx Pharmaceuticals20089.14 million78.71 millionOptionableCOYACoya Therapeutics616.73 million14.72 millionNot OptionableRAPPRapport TherapeuticsN/A36.50 millionN/AN/ARVNCRevance Therapeutics500104.39 million99.07 millionOptionableCOYA, RVNC, RAPP, and AMLX HeadlinesRecent News About These CompaniesRevance Names New CEO to Drive Next Phase in Aesthetic InnovationMay 23, 2025 | globalcosmeticsnews.comGRevance Announces Leadership Succession Plan to Support Next Phase of Growth and InnovationMay 21, 2025 | finance.yahoo.comCrown Laboratories Now Operates Under the Name RevanceMarch 31, 2025 | finance.yahoo.comJohnson City-based Crown Labs now operating as ‘Revance’March 31, 2025 | wjhl.comWREVANCE ALERT: Bragar Eagel & Squire, P.C. is Investigating Revance Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the FirmMarch 6, 2025 | globenewswire.comClass Action Filed Against Revance Therapeutics, Inc. (RVNC) Seeking Recovery for Investors - Contact Levi & KorsinskyMarch 4, 2025 | accessnewswire.comALevi & Korsinsky Notifies Revance Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - RVNCMarch 4, 2025 | accessnewswire.comARVNC DEADLINE TODAY: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Revance Therapeutics, Inc. Investors to Secure Counsel Before Important March 4 Deadline in Securities Class Action – RVNCMarch 4, 2025 | accessnewswire.comAContact Levi & Korsinsky by March 4, 2025 Deadline to Join Class Action Against Revance Therapeutics, Inc. (RVNC)March 4, 2025 | globenewswire.comContact Levi & Korsinsky by March 4, 2025 Deadline to Join Class Action Against Revance Therapeutics, Inc. (RVNC)March 4, 2025 | accessnewswire.comARevance Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Revance Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 4, 2025 - RVNCMarch 4, 2025 | accessnewswire.comAFINAL REMINDER RVNC DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Revance Therapeutics, Inc. Investors to Participate in the Class Action LawsuitMarch 4, 2025 | accessnewswire.comAInvestors who lost money on Revance Therapeutics, Inc.(RVNC) should contact Levi & Korsinsky about pending Class Action - RVNCMarch 4, 2025 | prnewswire.comInvestors who lost money on Revance Therapeutics, Inc.(RVNC) should contact Levi & Korsinsky about pending Class Action - RVNCMarch 3, 2025 | accessnewswire.comAMarch 4, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against RVNCMarch 3, 2025 | accessnewswire.comARVNC DEADLINE TOMORROW: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Revance Therapeutics, Inc. Investors to Secure Counsel Before Important March 4 Deadline in Securities Class Action – RVNCMarch 3, 2025 | globenewswire.comClass Action Filed Against Revance Therapeutics, Inc. (RVNC) - March 4, 2025 Deadline to Join - Contact Levi & KorsinskyMarch 3, 2025 | accessnewswire.comADeadline Soon: Revance Therapeutics, Inc. (RVNC) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud LawsuitMarch 3, 2025 | businesswire.comRevance Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – RVNCMarch 3, 2025 | globenewswire.comLevi & Korsinsky Notifies Shareholders of Revance Therapeutics, Inc. (RVNC) of a Class Action Lawsuit and an Upcoming DeadlineMarch 3, 2025 | accessnewswire.comANew MarketBeat Followers Over TimeMedia Sentiment Over TimeCOYA, RVNC, RAPP, and AMLX Company DescriptionsAmylyx Pharmaceuticals NASDAQ:AMLX$8.34 +0.06 (+0.72%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$8.39 +0.05 (+0.60%) As of 07/18/2025 07:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.Coya Therapeutics NASDAQ:COYA$5.81 -0.15 (-2.52%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$5.95 +0.14 (+2.48%) As of 07/18/2025 05:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.Rapport Therapeutics NASDAQ:RAPP$14.68 -0.16 (-1.08%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$14.70 +0.03 (+0.17%) As of 07/18/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.Revance Therapeutics NASDAQ:RVNCRevance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
